China SXT Pharmaceuticals, Inc. reported earnings results for the half year ended September 30, 2022. For the half year, the company reported sales was USD 1.21 million compared to USD 1.03 million a year ago. Revenue was USD 1.21 million compared to USD 1.03 million a year ago.

Net loss was USD 1.49 million compared to USD 3.09 million a year ago. Basic loss per share from continuing operations was USD 0.584 compared to USD 3.977 a year ago.